ARVO 2025: Update on the LIGHTSITE III study in AMD
At ARVO 2025, in Salt Lake City, Utah, Diana Do, MD, gave an update on the LIGHTSITE III study of photobiomodulation for dry age-related macular degeneration.
At ARVO 2025, in Salt Lake City, Utah, Diana Do, MD, gave an update on the LIGHTSITE III study of photobiomodulation for dry age-related macular degeneration.
At ARVO 2025, in Salt Lake City, Utah, Ferhina Ali, MD, MPH, talked about her presentation on the early real-world use of aflibercept 8 mg…
By analyzing subtle facial movements, researchers found ways to objectively measure the severity of tinnitus and sound sensitivity disorder symptoms.
LOS ANGELES — Ophthalmologists should act early to prevent a “vicious” cycle of neuropathy and inflammation in corneal disease, according to a speaker at the…
Surveillance screening every 3 to 6 months may not be necessary for patients with low-risk uveal melanoma, as metastasis rates appear to be low and…
In this episode, filmed in Chicago during the American Academy of Ophthalmology annual meeting, Sarwar Zahid, MD, sits down with Mitul Mehta, MD, to share…
The aim of this study was to identify predictive factors for spontaneous internal limiting membrane (ILM) peeling (SP) after idiopathic epiretinal membrane (ERM) removal and…
SYL1801 is an investigational siRNA therapy administered via eye drops, rather than intravitreal injection, to treat nAMD.
FORT LAUDERDALE, Fla. — In this Healio Video Perspective, Michael A. Singer, MD, discusses promising results for migaldendranib for the treatment of wet age-related macular…
Join moderators, faculty, and residents covering submitted case presentations, clinical pearls, and engaging panel discussions. Participate and earn CME at your convenience! This ASCRS Grand…
Did you know the sun’s ultraviolet (UV) rays can also damage the eyes? Here are some common questions and answers about UV light and how…